- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT03007147
Imatinibmesylaat en combinatiechemotherapie bij de behandeling van patiënten met nieuw gediagnosticeerde Philadelphia-chromosoompositieve acute lymfoblastische leukemie
Internationale fase 3-studie in Philadelphia chromosoom-positieve acute lymfoblastische leukemie (Ph+ALL) waarbij imatinib wordt getest in combinatie met twee verschillende cytotoxische chemotherapie-backbones
This randomized phase III trial studies how well imatinib mesylate works in combination with two different chemotherapy regimens in treating patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (ALL). Imatinib mesylate has been shown to improve outcomes in children and adolescents with Philadelphia chromosome positive (Ph+) ALL when given with strong chemotherapy, but the combination has many side effects. This trial is testing whether a different chemotherapy regimen may work as well as the stronger one but have fewer side effects when given with imatinib. The trial is also testing how well the combination of chemotherapy and imatinib works in another group of patients with a type of ALL that is similar to Ph+ ALL. This type of ALL is called "ABL-class fusion positive ALL", and because it is similar to Ph+ ALL, is thought it will respond well to the combination of agents used to treat Ph+ ALL.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
- Ander: Laboratory Biomarker Analysis
- Geneesmiddel: Cyclophosphamide
- Geneesmiddel: Doxorubicin
- Geneesmiddel: Vincristine Sulfate
- Ander: Questionnaire Administration
- Geneesmiddel: Daunorubicin Hydrochloride
- Geneesmiddel: Etoposide
- Geneesmiddel: Mercaptopurine
- Geneesmiddel: Methylprednisolone
- Geneesmiddel: Ifosfamide
- Geneesmiddel: Calaspargase Pegol
- Geneesmiddel: Leucovorin Calcium
- Geneesmiddel: Methotrexate
- Geneesmiddel: Cytarabine
- Geneesmiddel: Dexamethasone
- Geneesmiddel: Dexrazoxane Hydrochloride
- Biologisch: Filgrastim
- Geneesmiddel: Imatinib Mesylate
- Geneesmiddel: Levoleucovorin
- Geneesmiddel: Pegaspargase
- Geneesmiddel: Prednisolone
- Geneesmiddel: Therapeutic Hydrocortisone
- Geneesmiddel: Thioguanine
- Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Gedetailleerde beschrijving
PRIMARY OBJECTIVE:
I. To compare disease-free survival (DFS) of standard risk (SR) pediatric Philadelphia chromosome (Ph)+ acute lymphoblastic leukemia (ALL) treated with continuous imatinib mesylate (imatinib) combined with either a high-risk Children's Oncology Group (COG) ALL chemotherapy backbone or the more intensive European (Es)PhALL chemotherapy backbone.
SECONDARY OBJECTIVES:
I. To compare DFS of SR pediatric Ph+ and ABL-class fusion positive ALL patients treated with continuous imatinib combined with either a high-risk COG-ALL chemotherapy backbone or the more intensive EsPhALL chemotherapy backbone.
II. To determine the feasibility of administration of imatinib after allogeneic hematopoietic stem cell transplantation (HSCT) in high risk (HR) Ph+ ALL patients.
III. To determine event-free survival (EFS) of HR pediatric Ph+ ALL patients treated with EsPhALL chemotherapy, HSCT in first complete remission and post-HSCT imatinib.
IV. To compare rates of grade 3 or higher infections in standard risk (SR) Ph+ ALL patients between the two randomized arms.
V. To evaluate EFS and overall survival (OS) of all eligible Ph+ALL patients enrolled on the study.
VI. To evaluate OS in SR Ph+ ALL patients. VII. To evaluate OS in HR Ph+ ALL patients. VIII. To evaluate EFS and OS of all eligible ABL-class fusion positive ALL patients enrolled on the study.
EXPLORATORY OBJECTIVES:
I. To describe the toxicities associated with post-HSCT administration of imatinib in HR Ph+ALL patients.
II. To evaluate the long-term toxicities in SR Ph+ ALL patients treated with chemotherapy plus imatinib (no transplant), overall and between both randomized arms.
III. To determine prognostic significance of minimal residual disease (MRD) in Ph+ ALL at various time points during therapy.
IIIa. To evaluate MRD in HR patients just prior to HSCT and then at regular intervals post-HSCT and explore the association of these measurements with long-term outcome.
IIIb. To evaluate concordance of MRD assessments made by IGH-T cell receptor (TCR) polymerase chain reaction (PCR) assay and next generation sequencing (NGS) assays.
IV. To determine and validate if IKZF1 deletions alone (IKZF1del) or with other transcription factor deletions (ie, IKZF1 plus subtype [IKZF1plus]) or other identified genetic lesions predict poor outcomes in Ph+/ABL-class Ph-like ALL in patients treated on AALL1631.
V. To determine the frequency and prognostic significance of p190 and p210 BCR::ABL1 fusion variants in pediatric Ph+ ALL/ABL-class Ph-like ALL.
VI. To measure adherence to oral chemotherapeutic agents (imatinib, 6-mercaptopurine and methotrexate) during the maintenance phase in SR Ph+ ALL patients.
VIa. To identify factors associated with poor adherence. VIb. To determine association between relapse risk and adherence to each oral chemotherapeutic agent (separately and combined).
VII. To measure adherence to imatinib after allogeneic HSCT in HR Ph+ ALL patients and identify factors associated with poor adherence.
VIII. To compare DFS of SR ABL-class fusion positive ALL patients treated with continuous imatinib combined with either a high-risk COG-ALL chemotherapy backbone or the more intensive EsPhALL chemotherapy backbone.
IX. Other secondary and exploratory aims described above for Ph+ ALL patients (either SR or HR), if applicable, will be evaluated in ABL-class fusion positive ALL patients.
X. Secondary and exploratory aims described above for Ph+ ALL patients (either SR or HR), if applicable and feasible, will be evaluated in the super set of Ph+ and ABL-class fusion positive ALL patients.
XI. To determine the potential therapeutic impact of major secondary events via pharmacologic inhibitor screens in existing/engineered cell models of Ph+ and ABL-class Ph-like ALL harboring secondary events and to test the in vivo activity of the most compelling candidate compounds from pilot studies using patient-derived xenograft (PDX) models established from Ph+ and ABL-class Ph-like ALL samples collected from patients treated on AALL1631.
XII. To decipher the molecular and cellular heterogeneity of chronic myelogenous leukemia (CML)-like versus typical Ph+ ALL via single-cell genomics and functional assays and investigate CML-like phenotypes via single-cell ribonucleic acid (RNA) and deoxyribonucleic acid (DNA) sequencing to identify distinct transcriptomic and mutational profiles that will provide novel opportunities for diagnostic and therapeutic interventions.
OUTLINE:
INDUCTION IA PART 1: Patients receive induction IA according to standard of care on days 1-14.
INDUCTION IA PART 2: Patients receive imatinib mesylate orally (PO) once daily (QD) or twice daily (BID) on days 15-33, prednisolone PO twice daily (BID) or methylprednisolone intravenously (IV) on days 15-28, vincristine sulfate IV over 1 minute on days 15 and 22, daunorubicin hydrochloride IV over 1-15 minutes on days 15 and 22, and methotrexate intrathecally (IT) on day 29.
INDUCTION IB: Patients receive imatinib mesylate PO QD or BID on days 1-35, cyclophosphamide IV over 30-60 minutes on days 1 and 28, mercaptopurine PO on days 1-28, cytarabine IV or subcutaneously (SC) on days 3-6, 10-13, 17-20, and 24-27, and methotrexate IT on days 10 and 24.
POST-INDUCTION THERAPY: Patients classified as standard risk are randomized to 1 of 2 arms. Patients with high risk are assigned to Arm C.
ARM A (SR patients assigned to ARM A):
CONSOLIDATION BLOCK 1: Patients receive imatinib mesylate PO QD or BID on days 1-21, methotrexate IT, cytarabine IT, and therapeutic hydrocortisone IT on day 1, high dose methotrexate IV over 24 hours on day 1, vincristine sulfate IV over 1 minute on days 1 and 6, dexamethasone PO BID or IV on days 1-5, cyclophosphamide IV over 30-60 minutes on days 2-4, leucovorin calcium or levoleucovorin PO or IV on days 3 and 4, high dose cytarabine IV over 3 hours and pegaspargase or calaspargase pegol IV over 1-2 hours on day 5, and filgrastim SC or IV on days 7-11 in the absence of disease progression or unexpected toxicity.
CONSOLIDATION BLOCK 2: Patients receive imatinib mesylate PO QD or BID on days 1-21, methotrexate IT, cytarabine IT, and therapeutic hydrocortisone IT on day 1, high dose methotrexate IV over 24 hours on day 1, dexamethasone PO BID or IV on days 1-5, vincristine sulfate IV over 1 minute on days 1 and 6, ifosfamide IV over 1 hour on days 2-4, leucovorin calcium or levoleucovorin PO or IV on days 3 and 4, dexrazoxane hydrochloride IV over 15 minutes and daunorubicin hydrochloride IV over 1-15 minutes on day 5, pegaspargase or calaspargase pegol IV over 1-2 hours on day 6, and filgrastim SC or IV on days 7-11 in the absence of disease progression or unexpected toxicity.
CONSOLIDATION BLOCK 3: Patients receive imatinib mesylate PO QD or BID on days 1-21, high dose cytarabine IV over 3 hours on days 1-3, dexamethasone PO BID or IV on days 1-5, etoposide IV over 1-2 hours on days 3-5, methotrexate IT, cytarabine IT, and therapeutic hydrocortisone IT on day 5, pegaspargase or calaspargase pegol IV over 1-2 hours on day 6, and filgrastim SC or IV on days 7-11 in the absence of disease progression or unexpected toxicity.
DELAYED INTENSIFICATION 1 PART 1: Patients receive imatinib mesylate PO QD or BID on days 1-35, methotrexate IT on day 1, dexamethasone PO BID or IV on days 1-7 and 15-21, vincristine sulfate IV over 1 minute, dexrazoxane hydrochloride IV over 15 minutes, and doxorubicin IV over 3-15 minutes on days 8, 15, 22, and 29, and pegaspargase or calaspargase pegol IV over 1-2 hours on day 8 in the absence of disease progression or unexpected toxicity.
DELAYED INTENSIFICATION 1 PART 2: Patients receive imatinib mesylate PO QD on days 36-63, cyclophosphamide IV over 30-60 minutes on day 36, thioguanine PO on days 36-49, cytarabine IV over 1-30 minutes or SC on days 38-41 and 45-48, and methotrexate IT on days 38 and 45in the absence of disease progression or unexpected toxicity.
INTERIM MAINTENANCE: Patients receive imatinib mesylate PO QD or BID on days 1-28, methotrexate PO on days 1, 8, 15, and 22, and mercaptopurine PO on days 1-28 in the absence of disease progression or unexpected toxicity.
DELAYED INTENSIFICATION 2 PART 1: Patients receive imatinib mesylate PO QD or BID on days 1-35, methotrexate IT on day 1, dexamethasone PO BID or IV on days 1-7 and 15-21, vincristine sulfate IV over 1 minute, dexrazoxane hydrochloride IV over 15 minutes, and doxorubicin IV over 3-15 minutes on days 8, 15, 22, and 29, and pegaspargase or calaspargase pegol IV over 1-2 hours on day 8 in the absence of disease progression or unexpected toxicity.
DELAYED INTENSIFICATION 2 PART 2: Patients receive imatinib mesylate PO QD on days 36-49, cyclophosphamide IV over 30-60 minutes on day 36, thioguanine PO on days 36-49, cytarabine IV over 1-30 minutes or SC on days 36-39 and 43-46, and methotrexate IT on days 36 and 43 in the absence of disease progression or unexpected toxicity.
MAINTENANCE: Patients receive imatinib mesylate PO QD or BID on days 1-84, methotrexate PO once weekly (QW) and IT on days 1 and 43 of cycles 1, 2, and 3, and mercaptopurine PO on days 1-84. Cycles with imatinib mesylate and mercaptopurine repeat every 84 days for up to 104 weeks from the start of Induction IA in the absence of disease progression or unexpected toxicity.
ARM B (SR PATIENTS ASSIGNED TO ARM B):
INTERIM MAINTENANCE: Patients receive imatinib mesylate PO QD or BID on days 1-63, vincristine sulfate IV over 1 minute and high dose methotrexate IV over 24 hours on days 1, 15, 29, and 43, leucovorin calcium or levoleucovorin PO or IV on days 3-4, 17-18, 31-32, and 45-46, mercaptopurine PO on days 1-56, and methotrexate IT on days 1 and 29 in the absence of disease progression or unexpected toxicity.
DELAYED INTENSIFICATION PART 1: Patients receive imatinib mesylate PO QD or BID on days 1-28, methotrexate IT on day 1, dexamethasone PO BID or IV on days 1-7 and 15-21, vincristine sulfate IV over 1 minute, dexrazoxane hydrochloride IV over 15 minutes, and doxorubicin IV over 3-15 minutes on days 1, 8, and 15, and pegaspargase or calaspargase pegol IV over 1-2 hours or IM on day 4 in the absence of disease progression or unexpected toxicity.
DELAYED INTENSIFICATION PART 2: Patients receive imatinib mesylate PO QD on days 29-56, cyclophosphamide IV over 30-60 minutes on day 29, thioguanine PO on days 29-42, cytarabine IV over 1-30 minutes or SC on days 29-32 and 36-39, methotrexate IT on days 29 and 36, vincristine sulfate IV over 1 minute on days 43 and 50, and pegaspargase or calaspargase pegol IV over 1-2 hours on day 43 in the absence of disease progression or unexpected toxicity.
INTERIM MAINTENANCE WITH CAPIZZI METHOTREXATE: Patients receive imatinib mesylate PO QD or BID on days 1-56, vincristine sulfate IV over 1 minute and methotrexate IV over 2-15 minutes on days 1, 11, 21, 31, and 41, methotrexate IT on days 1 and 31, and pegaspargase or calaspargase pegol IV over 1-2 hours on days 2 and 23 in the absence of disease progression or unexpected toxicity.
MAINTENANCE: Patients receive imatinib mesylate PO QD or BID on days 1-84, vincristine sulfate IV over 1 minute on days 1, 29, and 57, prednisolone PO BID (or methylprednisolone IV for cycle 1 and 2) on days 1-5, 29-33, and 57-61, mercaptopurine PO on days 1-84, methotrexate PO QW, and methotrexate IT on day 1 (and day 29 for cycle 1 and 2). Cycles repeat every 84 days for up to 104 weeks from the start of Induction IA in the absence of disease progression or unexpected toxicity.
ARM C (HR PATIENTS):
CONSOLIDATION BLOCK 1: Patients receive imatinib mesylate, methotrexate, cytarabine, therapeutic hydrocortisone, high dose methotrexate, vincristine sulfate, dexamethasone, leucovorin calcium or levoleucovorin, high dose cytarabine, and pegaspargase or calaspargase pegol as in Arm A Consolidation Block 1, and filgrastim SC or IV on day 7 in the absence of disease progression or unexpected toxicity.
CONSOLIDATION BLOCK 2: Patients receive imatinib mesylate, methotrexate, cytarabine, therapeutic hydrocortisone, high dose methotrexate, dexamethasone, vincristine sulfate, ifosfamide, leucovorin calcium or levoleucovorin, dexrazoxane hydrochloride, daunorubicin hydrochloride, pegaspargase or calaspargase pegol, and filgrastim as Arm A Consolidation Block 2 in the absence of disease progression or unexpected toxicity.
CONSOLIDATION BLOCK 3: Patients receive imatinib mesylate, dexamethasone, etoposide, methotrexate, cytarabine, therapeutic hydrocortisone, pegaspargase or calaspargase pegol, and filgrastim as in Arm A Consolidation Block 3, and high dose cytarabine IV over 3 hours on days 1-2 in the absence of disease progression or unexpected toxicity.
HSCT: Patients undergo HSCT on day 0. Patients who do not proceed to HSCT receive Delayed Intensification 1, Interim Maintenance, Delayed Intensification 2, and Maintenance as in Arm A.
POST-HSCT: Patients receive imatinib mesylate PO QD or BID starting on days 56-365 in the in the absence of disease progression or unexpected toxicity.
After completion of study treatment, patients are followed up every year for 3 years.
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 3
Contacten en locaties
Studie Locaties
-
-
New South Wales
-
Hunter Regional Mail Centre, New South Wales, Australië, 2310
- John Hunter Children's Hospital
-
Randwick, New South Wales, Australië, 2031
- Sydney Children's Hospital
-
Westmead, New South Wales, Australië, 2145
- The Children's Hospital at Westmead
-
-
Queensland
-
South Brisbane, Queensland, Australië, 4101
- Queensland Children's Hospital
-
-
Western Australia
-
Perth, Western Australia, Australië, 6008
- Princess Margaret Hospital for Children
-
Perth, Western Australia, Australië, 6009
- Perth Children's Hospital
-
-
-
-
Flemish Brabant
-
Leuven, Flemish Brabant, België, 3000
- Hospitals Leuven
-
-
-
-
-
Québec, Canada, G1V 4G2
- CHU de Quebec-Centre Hospitalier de l'Universite Laval (CHUL)
-
-
Alberta
-
Calgary, Alberta, Canada, T3B 6A8
- Alberta Children's Hospital
-
Edmonton, Alberta, Canada, T6G 2B7
- University of Alberta Hospital
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V6H 3V4
- British Columbia Children's Hospital
-
-
Manitoba
-
Winnipeg, Manitoba, Canada, R3E 0V9
- CancerCare Manitoba
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canada, B3K 6R8
- IWK Health Centre
-
-
Ontario
-
Hamilton, Ontario, Canada, L8N 3Z5
- McMaster Children's Hospital at Hamilton Health Sciences
-
Kingston, Ontario, Canada, K7L 2V7
- Kingston Health Sciences Centre
-
London, Ontario, Canada, N6A 5W9
- Children's Hospital
-
Ottawa, Ontario, Canada, K1H 8L1
- Children's Hospital of Eastern Ontario
-
Toronto, Ontario, Canada, M5G 1X8
- Hospital for Sick Children
-
-
Quebec
-
Montreal, Quebec, Canada, H3H 1P3
- The Montreal Children's Hospital of the MUHC
-
Montreal, Quebec, Canada, H3T 1C5
- Centre Hospitalier Universitaire Sainte-Justine
-
Sherbrooke, Quebec, Canada, J1H 5N4
- Centre Hospitalier Universitaire de Sherbrooke-Fleurimont
-
-
Saskatchewan
-
Saskatoon, Saskatchewan, Canada, S7N 4H4
- Saskatoon Cancer Centre
-
Saskatoon, Saskatchewan, Canada, S7N 0W8
- Jim Pattison Children's Hospital
-
-
-
-
-
Santiago, Chili
- Hospital Roberto del Rio-Universidad de Chile
-
-
-
-
-
Hamburg, Duitsland, 20246
- Universitätsklinik Eppendorf
-
-
Schleswig-Holstein
-
Kiel, Schleswig-Holstein, Duitsland, 24105
- University Medical Center chleswig- Campus Kiel
-
-
-
-
-
Tampere, Finland, 33521
- Tampere University Hospital
-
-
-
-
-
Rennes, Frankrijk, 35203
- CHU Hopital Sud
-
-
-
-
Kowloon
-
Kowloon Bay, Kowloon, Hongkong
- Hong Kong Children's Hospital
-
-
-
-
Central District
-
Petah Tikva, Central District, Israël, 4920235
- Schneider Children's Medical Center of Israel
-
-
-
-
-
Monza, Italië, 20900
- Clinica Pediatrica Università Milano-Bicocca Ospedale S. Gerardo/Fondazione MBBM
-
-
-
-
-
Utrecht, Nederland, 3584 CT
- Princess Máxima Center for Pediatric Oncology
-
-
-
-
-
Christchurch, Nieuw-Zeeland, 8011
- Christchurch Hospital
-
-
Auckland
-
Grafton, Auckland, Nieuw-Zeeland, 1145
- Starship Children's Hospital
-
-
-
-
-
Vienna, Oostenrijk, 1090
- St. Anna Children's Hospital
-
-
-
-
-
Caguas, Puerto Rico, 00726
- HIMA San Pablo Oncologic Hospital
-
San Juan, Puerto Rico, 00926
- University Pediatric Hospital
-
San Juan, Puerto Rico, 00912
- San Jorge Children's Hospital
-
-
-
-
-
Riyadh, Saoedi-Arabië, 11211
- King Faisal Specialist Hospital and Research Centre
-
-
-
-
-
Prague, Tsjechië, 15018, 5-Motol
- University Hospital Motol
-
-
-
-
Alabama
-
Birmingham, Alabama, Verenigde Staten, 35233
- Children's Hospital of Alabama
-
Mobile, Alabama, Verenigde Staten, 36604
- USA Health Strada Patient Care Center
-
-
Alaska
-
Anchorage, Alaska, Verenigde Staten, 99508
- Providence Alaska Medical Center
-
-
Arizona
-
Mesa, Arizona, Verenigde Staten, 85202
- Banner Children's at Desert
-
Phoenix, Arizona, Verenigde Staten, 85016
- Phoenix Childrens Hospital
-
Tucson, Arizona, Verenigde Staten, 85719
- Banner University Medical Center - Tucson
-
-
Arkansas
-
Little Rock, Arkansas, Verenigde Staten, 72202-3591
- Arkansas Children's Hospital
-
-
California
-
Downey, California, Verenigde Staten, 90242
- Kaiser Permanente Downey Medical Center
-
Duarte, California, Verenigde Staten, 91010
- City of Hope Comprehensive Cancer Center
-
Loma Linda, California, Verenigde Staten, 92354
- Loma Linda University Medical Center
-
Long Beach, California, Verenigde Staten, 90806
- Miller Children's and Women's Hospital Long Beach
-
Los Angeles, California, Verenigde Staten, 90048
- Cedars-Sinai Medical Center
-
Los Angeles, California, Verenigde Staten, 90027
- Children's Hospital Los Angeles
-
Madera, California, Verenigde Staten, 93636
- Valley Children's Hospital
-
Oakland, California, Verenigde Staten, 94609
- UCSF Benioff Children's Hospital Oakland
-
Oakland, California, Verenigde Staten, 94611
- Kaiser Permanente-Oakland
-
Orange, California, Verenigde Staten, 92868
- Children's Hospital of Orange County
-
Palo Alto, California, Verenigde Staten, 94304
- Lucile Packard Children's Hospital Stanford University
-
Sacramento, California, Verenigde Staten, 95817
- University of California Davis Comprehensive Cancer Center
-
San Diego, California, Verenigde Staten, 92123
- Rady Children's Hospital - San Diego
-
San Francisco, California, Verenigde Staten, 94158
- UCSF Medical Center-Mission Bay
-
-
Colorado
-
Aurora, Colorado, Verenigde Staten, 80045
- Children's Hospital Colorado
-
Denver, Colorado, Verenigde Staten, 80218
- Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center
-
-
Connecticut
-
Hartford, Connecticut, Verenigde Staten, 06106
- Connecticut Children's Medical Center
-
New Haven, Connecticut, Verenigde Staten, 06520
- Yale University
-
-
Delaware
-
Wilmington, Delaware, Verenigde Staten, 19803
- Alfred I duPont Hospital for Children
-
-
District of Columbia
-
Washington D.C., District of Columbia, Verenigde Staten, 20010
- Children's National Medical Center
-
Washington D.C., District of Columbia, Verenigde Staten, 20007
- MedStar Georgetown University Hospital
-
-
Florida
-
Fort Lauderdale, Florida, Verenigde Staten, 33316
- Broward Health Medical Center
-
Fort Myers, Florida, Verenigde Staten, 33908
- Golisano Children's Hospital of Southwest Florida
-
Gainesville, Florida, Verenigde Staten, 32610
- UF Health Cancer Institute - Gainesville
-
Hollywood, Florida, Verenigde Staten, 33021
- Memorial Regional Hospital/Joe DiMaggio Children's Hospital
-
Jacksonville, Florida, Verenigde Staten, 32207
- Nemours Children's Clinic-Jacksonville
-
Loxahatchee Groves, Florida, Verenigde Staten, 33470
- Palms West Radiation Therapy
-
Miami, Florida, Verenigde Staten, 33155
- Nicklaus Children's Hospital
-
Miami, Florida, Verenigde Staten, 33136
- University of Miami Miller School of Medicine-Sylvester Cancer Center
-
Miami, Florida, Verenigde Staten, 33176
- Miami Cancer Institute
-
Orlando, Florida, Verenigde Staten, 32827
- Nemours Children's Hospital
-
Orlando, Florida, Verenigde Staten, 32803
- AdventHealth Orlando
-
Orlando, Florida, Verenigde Staten, 32806
- Arnold Palmer Hospital for Children
-
Pensacola, Florida, Verenigde Staten, 32504
- Sacred Heart Hospital
-
St. Petersburg, Florida, Verenigde Staten, 33701
- Johns Hopkins All Children's Hospital
-
Tampa, Florida, Verenigde Staten, 33606
- Tampa General Hospital
-
Tampa, Florida, Verenigde Staten, 33607
- Saint Joseph's Hospital/Children's Hospital-Tampa
-
West Palm Beach, Florida, Verenigde Staten, 33407
- Saint Mary's Medical Center
-
-
Georgia
-
Atlanta, Georgia, Verenigde Staten, 30329
- Children's Healthcare of Atlanta - Arthur M Blank Hospital
-
Augusta, Georgia, Verenigde Staten, 30912
- Augusta University Medical Center
-
Macon, Georgia, Verenigde Staten, 31201
- Atrium Health Navicent
-
Savannah, Georgia, Verenigde Staten, 31404
- Memorial Health University Medical Center
-
-
Hawaii
-
Honolulu, Hawaii, Verenigde Staten, 96826
- Kapiolani Medical Center for Women and Children
-
-
Idaho
-
Boise, Idaho, Verenigde Staten, 83712
- Saint Luke's Cancer Institute - Boise
-
-
Illinois
-
Chicago, Illinois, Verenigde Staten, 60637
- University of Chicago Comprehensive Cancer Center
-
Chicago, Illinois, Verenigde Staten, 60612
- University of Illinois
-
Chicago, Illinois, Verenigde Staten, 60611
- Lurie Children's Hospital-Chicago
-
Oak Lawn, Illinois, Verenigde Staten, 60453
- Advocate Children's Hospital-Oak Lawn
-
Park Ridge, Illinois, Verenigde Staten, 60068
- Advocate Children's Hospital-Park Ridge
-
Peoria, Illinois, Verenigde Staten, 61637
- OSF Children's Hospital of Illinois
-
Springfield, Illinois, Verenigde Staten, 62702
- Southern Illinois University School of Medicine
-
-
Indiana
-
Indianapolis, Indiana, Verenigde Staten, 46202
- Riley Hospital for Children
-
Indianapolis, Indiana, Verenigde Staten, 46260
- Ascension Saint Vincent Indianapolis Hospital
-
-
Iowa
-
Des Moines, Iowa, Verenigde Staten, 50309
- Blank Children's Hospital
-
Iowa City, Iowa, Verenigde Staten, 52242
- University of Iowa/Holden Comprehensive Cancer Center
-
-
Kentucky
-
Lexington, Kentucky, Verenigde Staten, 40536
- University of Kentucky/Markey Cancer Center
-
Louisville, Kentucky, Verenigde Staten, 40202
- Norton Children's Hospital
-
-
Louisiana
-
New Orleans, Louisiana, Verenigde Staten, 70121
- Ochsner Medical Center Jefferson
-
-
Maine
-
Bangor, Maine, Verenigde Staten, 04401
- Eastern Maine Medical Center
-
Scarborough, Maine, Verenigde Staten, 04074
- Maine Children's Cancer Program
-
-
Maryland
-
Baltimore, Maryland, Verenigde Staten, 21287
- Johns Hopkins University/Sidney Kimmel Cancer Center
-
Baltimore, Maryland, Verenigde Staten, 21215
- Sinai Hospital of Baltimore
-
Bethesda, Maryland, Verenigde Staten, 20889-5600
- Walter Reed National Military Medical Center
-
-
Massachusetts
-
Boston, Massachusetts, Verenigde Staten, 02215
- Dana-Farber Cancer Institute
-
Boston, Massachusetts, Verenigde Staten, 02114
- Massachusetts General Hospital Cancer Center
-
Boston, Massachusetts, Verenigde Staten, 02111
- Tufts Children's Hospital
-
Worcester, Massachusetts, Verenigde Staten, 01655
- UMass Memorial Medical Center - University Campus
-
-
Michigan
-
Ann Arbor, Michigan, Verenigde Staten, 48109
- C S Mott Children's Hospital
-
Detroit, Michigan, Verenigde Staten, 48201
- Children's Hospital of Michigan
-
Detroit, Michigan, Verenigde Staten, 48236
- Henry Ford Health Saint John Hospital
-
East Lansing, Michigan, Verenigde Staten, 48823
- Michigan State University
-
Grand Rapids, Michigan, Verenigde Staten, 49503
- Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital
-
Kalamazoo, Michigan, Verenigde Staten, 49007
- Bronson Methodist Hospital
-
Royal Oak, Michigan, Verenigde Staten, 48073
- Corewell Health Children's
-
-
Minnesota
-
Minneapolis, Minnesota, Verenigde Staten, 55404
- Children's Hospitals and Clinics of Minnesota - Minneapolis
-
Minneapolis, Minnesota, Verenigde Staten, 55455
- University of Minnesota/Masonic Cancer Center
-
-
Mississippi
-
Jackson, Mississippi, Verenigde Staten, 39216
- University of Mississippi Medical Center
-
-
Missouri
-
Columbia, Missouri, Verenigde Staten, 65212
- University of Missouri Children's Hospital
-
Kansas City, Missouri, Verenigde Staten, 64108
- Children's Mercy Hospitals and Clinics
-
St Louis, Missouri, Verenigde Staten, 63110
- Washington University School of Medicine
-
St Louis, Missouri, Verenigde Staten, 63141
- Mercy Hospital Saint Louis
-
-
Nebraska
-
Omaha, Nebraska, Verenigde Staten, 68198
- University of Nebraska Medical Center
-
Omaha, Nebraska, Verenigde Staten, 68114
- Children's Hospital and Medical Center of Omaha
-
-
Nevada
-
Las Vegas, Nevada, Verenigde Staten, 89144
- Summerlin Hospital Medical Center
-
Las Vegas, Nevada, Verenigde Staten, 89109
- Sunrise Hospital and Medical Center
-
Las Vegas, Nevada, Verenigde Staten, 89135
- Alliance for Childhood Diseases/Cure 4 the Kids Foundation
-
Las Vegas, Nevada, Verenigde Staten, 89102
- University Medical Center of Southern Nevada
-
Reno, Nevada, Verenigde Staten, 89502
- Renown Regional Medical Center
-
-
New Hampshire
-
Lebanon, New Hampshire, Verenigde Staten, 03756
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
-
-
New Jersey
-
Hackensack, New Jersey, Verenigde Staten, 07601
- Hackensack University Medical Center
-
Morristown, New Jersey, Verenigde Staten, 07960
- Morristown Medical Center
-
Neptune City, New Jersey, Verenigde Staten, 07753
- Jersey Shore Medical Center
-
New Brunswick, New Jersey, Verenigde Staten, 08901
- Saint Peter's University Hospital
-
New Brunswick, New Jersey, Verenigde Staten, 08903
- Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital
-
Newark, New Jersey, Verenigde Staten, 07112
- Newark Beth Israel Medical Center
-
Paterson, New Jersey, Verenigde Staten, 07503
- Saint Joseph's Regional Medical Center
-
-
New Mexico
-
Albuquerque, New Mexico, Verenigde Staten, 87106
- Presbyterian Hospital
-
Albuquerque, New Mexico, Verenigde Staten, 87106
- University of New Mexico Cancer Center
-
-
New York
-
Albany, New York, Verenigde Staten, 12208
- Albany Medical Center
-
Brooklyn, New York, Verenigde Staten, 11219
- Maimonides Medical Center
-
Buffalo, New York, Verenigde Staten, 14263
- Roswell Park Cancer Institute
-
Mineola, New York, Verenigde Staten, 11501
- NYU Langone Hospital - Long Island
-
New Hyde Park, New York, Verenigde Staten, 11040
- The Steven and Alexandra Cohen Children's Medical Center of New York
-
New York, New York, Verenigde Staten, 10065
- Memorial Sloan Kettering Cancer Center
-
New York, New York, Verenigde Staten, 10029
- Mount Sinai Hospital
-
New York, New York, Verenigde Staten, 10032
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
-
New York, New York, Verenigde Staten, 10016
- Laura and Isaac Perlmutter Cancer Center at NYU Langone
-
Rochester, New York, Verenigde Staten, 14642
- University of Rochester
-
Stony Brook, New York, Verenigde Staten, 11794
- Stony Brook University Medical Center
-
Syracuse, New York, Verenigde Staten, 13210
- State University of New York Upstate Medical University
-
The Bronx, New York, Verenigde Staten, 10467
- Montefiore Medical Center - Moses Campus
-
Valhalla, New York, Verenigde Staten, 10595
- New York Medical College
-
-
North Carolina
-
Asheville, North Carolina, Verenigde Staten, 28801
- Mission Hospital
-
Chapel Hill, North Carolina, Verenigde Staten, 27599
- UNC Lineberger Comprehensive Cancer Center
-
Charlotte, North Carolina, Verenigde Staten, 28203
- Carolinas Medical Center/Levine Cancer Institute
-
Charlotte, North Carolina, Verenigde Staten, 28204
- Novant Health Presbyterian Medical Center
-
Durham, North Carolina, Verenigde Staten, 27710
- Duke University Medical Center
-
Greenville, North Carolina, Verenigde Staten, 27834
- East Carolina University
-
Winston-Salem, North Carolina, Verenigde Staten, 27157
- Wake Forest University Health Sciences
-
-
North Dakota
-
Fargo, North Dakota, Verenigde Staten, 58122
- Sanford Broadway Medical Center
-
-
Ohio
-
Akron, Ohio, Verenigde Staten, 44308
- Children's Hospital Medical Center of Akron
-
Cincinnati, Ohio, Verenigde Staten, 45229
- Cincinnati Children's Hospital Medical Center
-
Cleveland, Ohio, Verenigde Staten, 44195
- Cleveland Clinic Foundation
-
Cleveland, Ohio, Verenigde Staten, 44106
- Rainbow Babies and Childrens Hospital
-
Columbus, Ohio, Verenigde Staten, 43205
- Nationwide Children's Hospital
-
Dayton, Ohio, Verenigde Staten, 45404
- Dayton Children's Hospital
-
Toledo, Ohio, Verenigde Staten, 43606
- ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Verenigde Staten, 73104
- University of Oklahoma Health Sciences Center
-
-
Oregon
-
Portland, Oregon, Verenigde Staten, 97239
- Oregon Health and Science University
-
Portland, Oregon, Verenigde Staten, 97227
- Legacy Emanuel Children's Hospital
-
-
Pennsylvania
-
Allentown, Pennsylvania, Verenigde Staten, 18103
- Lehigh Valley Hospital-Cedar Crest
-
Danville, Pennsylvania, Verenigde Staten, 17822
- Geisinger Medical Center
-
Hershey, Pennsylvania, Verenigde Staten, 17033
- Penn State Children's Hospital
-
Philadelphia, Pennsylvania, Verenigde Staten, 19104
- Children's Hospital of Philadelphia
-
Philadelphia, Pennsylvania, Verenigde Staten, 19134
- Saint Christopher's Hospital for Children
-
Pittsburgh, Pennsylvania, Verenigde Staten, 15224
- Children's Hospital of Pittsburgh of UPMC
-
-
Rhode Island
-
Providence, Rhode Island, Verenigde Staten, 02903
- Rhode Island Hospital
-
-
South Carolina
-
Charleston, South Carolina, Verenigde Staten, 29425
- Medical University of South Carolina
-
Columbia, South Carolina, Verenigde Staten, 29203
- Prisma Health Richland Hospital
-
Greenville, South Carolina, Verenigde Staten, 29605
- BI-LO Charities Children's Cancer Center
-
-
South Dakota
-
Sioux Falls, South Dakota, Verenigde Staten, 57117-5134
- Sanford USD Medical Center - Sioux Falls
-
-
Tennessee
-
Chattanooga, Tennessee, Verenigde Staten, 37403
- T C Thompson Children's Hospital
-
Knoxville, Tennessee, Verenigde Staten, 37916
- East Tennessee Childrens Hospital
-
Nashville, Tennessee, Verenigde Staten, 37232
- Vanderbilt University/Ingram Cancer Center
-
Nashville, Tennessee, Verenigde Staten, 37203
- The Children's Hospital at TriStar Centennial
-
-
Texas
-
Amarillo, Texas, Verenigde Staten, 79106
- Texas Tech University Health Sciences Center-Amarillo
-
Austin, Texas, Verenigde Staten, 78723
- Dell Children's Medical Center of Central Texas
-
Corpus Christi, Texas, Verenigde Staten, 78411
- Driscoll Children's Hospital
-
Dallas, Texas, Verenigde Staten, 75390
- UT Southwestern/Simmons Cancer Center-Dallas
-
Dallas, Texas, Verenigde Staten, 75230
- Medical City Dallas Hospital
-
El Paso, Texas, Verenigde Staten, 79905
- El Paso Children's Hospital
-
Fort Worth, Texas, Verenigde Staten, 76104
- Cook Children's Medical Center
-
Houston, Texas, Verenigde Staten, 77030
- UT MD Anderson Cancer Center
-
Houston, Texas, Verenigde Staten, 77030
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
-
Lubbock, Texas, Verenigde Staten, 79410
- Covenant Children's Hospital
-
Lubbock, Texas, Verenigde Staten, 79415
- UMC Cancer Center / UMC Health System
-
San Antonio, Texas, Verenigde Staten, 78207
- Children's Hospital of San Antonio
-
San Antonio, Texas, Verenigde Staten, 78229
- Methodist Children's Hospital of South Texas
-
Temple, Texas, Verenigde Staten, 76508
- Scott and White Memorial Hospital
-
-
Utah
-
Salt Lake City, Utah, Verenigde Staten, 84113
- Primary Children's Hospital
-
-
Vermont
-
Burlington, Vermont, Verenigde Staten, 05405
- University of Vermont and State Agricultural College
-
-
Virginia
-
Charlottesville, Virginia, Verenigde Staten, 22908
- University of Virginia Cancer Center
-
Falls Church, Virginia, Verenigde Staten, 22042
- Inova Fairfax Hospital
-
Norfolk, Virginia, Verenigde Staten, 23507
- Children's Hospital of The King's Daughters
-
Portsmouth, Virginia, Verenigde Staten, 23708-2197
- Naval Medical Center - Portsmouth
-
Richmond, Virginia, Verenigde Staten, 23298
- VCU Massey Comprehensive Cancer Center
-
Roanoke, Virginia, Verenigde Staten, 24014
- Carilion Children's
-
-
Washington
-
Seattle, Washington, Verenigde Staten, 98105
- Seattle Children's Hospital
-
Spokane, Washington, Verenigde Staten, 99204
- Providence Sacred Heart Medical Center and Children's Hospital
-
Tacoma, Washington, Verenigde Staten, 98405
- Mary Bridge Children's Hospital and Health Center
-
Tacoma, Washington, Verenigde Staten, 98431
- Madigan Army Medical Center
-
-
West Virginia
-
Huntington, West Virginia, Verenigde Staten, 25701
- Edwards Comprehensive Cancer Center
-
Morgantown, West Virginia, Verenigde Staten, 26506
- West Virginia University Healthcare
-
-
Wisconsin
-
Green Bay, Wisconsin, Verenigde Staten, 54301
- Saint Vincent Hospital Cancer Center Green Bay
-
Madison, Wisconsin, Verenigde Staten, 53792
- University of Wisconsin Carbone Cancer Center - University Hospital
-
Marshfield, Wisconsin, Verenigde Staten, 54449
- Marshfield Medical Center-Marshfield
-
Milwaukee, Wisconsin, Verenigde Staten, 53226
- Children's Hospital of Wisconsin
-
-
-
-
Skåne County
-
Lund, Skåne County, Zweden, 22185
- Skane University Hospital
-
-
-
-
-
Zurich, Zwitserland, CH8032
- University Children's Hospital
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
-
For patients enrolled on APEC14B1 prior to enrollment on AALL1631, the required diagnostic bone marrow sample has been fulfilled
- For patients who have not previously enrolled on APEC14B1 prior to enrollment on AALL1631, a baseline diagnostic sample (or peripheral blood sample with blasts if marrow sample unavailable) must be available to develop an MRD probe
- In addition, laboratory reports detailing evidence of BCR::ABL1 fusion or ABL-class fusion must be submitted for rapid central review within 72 hours of study enrollment
-
>= 1 year (365 days) and =< 21 years at ALL diagnosis
-
Ph+ (BCR::ABL1 fusion): newly diagnosed de novo ALL (B-ALL or T-ALL) or mixed phenotypic acute leukemia (MPAL meeting 2016 World Health Organization [WHO] definition) with definitive evidence of BCR::ABL1 fusion by karyotype, fluorescence in situ hybridization (FISH) and/or molecular methodologies
-
ABL-class fusion: newly diagnosed B-ALL with definitive evidence of ABL-class fusions. ABL-class fusions are defined as those involving the following genes: ABL1, ABL2, CSF1R, PDGFRB, PDGFRA. Methods of detection include fluorescence in-situ hybridization ([FISH], e.g. using break-apart or colocalization signals probes), multiplex or singleplex reverse-transcription polymerase chain reaction (RT-PCR), whole transcriptome or panel-based RNA-sequencing (e.g. TruSight RNA Pan-Cancer Panel; Illumina, San Diego, California [CA], United States of America [USA] or similar)
-
Ph+ patients must have previously started Induction therapy, which includes vincristine, a corticosteroid, pegaspargase, with or without anthracycline, and/or other standard cytotoxic chemotherapy
-
Ph+ patients have not received more than 14 days of multiagent Induction therapy beginning with the first dose of vinCRIStine
-
Ph+ patients may have started imatinib prior to study entry but have not received more than 14 days of imatinib
-
ABL-class fusion patients must have previously completed the 4 or 5 weeks of multiagent Induction chemotherapy (Induction IA phase)
-
ABL-class fusion patients may have started imatinib during Induction IA, at the same time of or after the first vinCRIStine dose
-
Patients must have a performance status corresponding to Eastern Cooperative Oncology Group (ECOG) scores of 0, 1, or 2
-
Direct bilirubin =< 2.0 mg/dL
-
Shortening fraction of >= 27% by echocardiogram
-
Ejection fraction of >= 50% by radionuclide angiogram or echocardiogram
-
Corrected QT interval, QTc < 480 msec
- Note: Repeat echocardiogram and electrocardiogram are not required if they were performed at or after initial ALL diagnosis, before study enrollment
-
Creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70 mL/min/1.73 m^2 or serum creatinine within normal limits based on age/gender, as follows:
- 1 to < 2 years: maximum serum creatinine 0.6 mg/dL (both male and female)
- 2 to < 6 years: maximum serum creatinine 0.8 mg/dL (both male and female)
- 6 to < 10 years: maximum serum creatinine 1 mg/dL (both male and female)
- 10 to < 13 years: maximum serum creatinine 1.2 mg/dL (both male and female)
- 13 to < 16 years: maximum serum creatinine 1.5 mg/dL (male), 1.4 mg/dL (female)
- >= 16 years: maximum serum creatinine 1.7 mg/dL (male), 1.4 mg/dL (female)
Exclusion Criteria:
-
Known history of chronic myelogenous leukemia (CML)
-
ALL developing after a previous cancer treated with cytotoxic chemotherapy
-
Active, uncontrolled infection, or active systemic illness that requires ongoing vasopressor support or mechanical ventilation
-
Down syndrome
-
Pregnancy and breast feeding
- Female patients who are pregnant since fetal toxicities and teratogenic effects have been noted for several of the study drugs. A pregnancy test is required for female patients of childbearing potential
- Lactating females who plan to breastfeed their infants
- Sexually active patients of reproductive potential who have not agreed to use an effective contraceptive method for the duration of treatment according to protocol
-
Patients with congenital long QT syndrome, history of ventricular arrhythmias or heart block
-
Prior treatment with dasatinib, or any TKI other than imatinib
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Arm A (imatinib mesylate, EsPhALL chemotherapy)
See Detailed Description |
Correlative studies Given IV
Andere namen:
Given IV
Andere namen:
Given IV
Andere namen:
Ancillary studies Given IV
Andere namen:
Given IV
Andere namen:
Given PO
Andere namen:
Given IV
Andere namen:
Given IV
Andere namen:
Given IV
Andere namen:
Given PO or IV
Andere namen:
Given IT
Andere namen:
Given IV, SC, or IT
Andere namen:
Given PO or IV
Andere namen:
Given IV
Andere namen:
Given SC or IV
Andere namen:
Given PO
Andere namen:
Given PO or IV
Andere namen:
Given IV
Andere namen:
Given PO
Andere namen:
Given IT
Andere namen:
Given PO
Andere namen:
|
|
Experimenteel: Arm B (imatinib mesylate, COG/BFM chemotherapy)
See Detailed Description. |
Correlative studies Given IV
Andere namen:
Given IV
Andere namen:
Given IV
Andere namen:
Ancillary studies Given PO
Andere namen:
Given IV
Andere namen:
Given IV
Andere namen:
Given PO or IV
Andere namen:
Given IT
Andere namen:
Given IV, SC, or IT
Andere namen:
Given PO or IV
Andere namen:
Given IV
Andere namen:
Given PO
Andere namen:
Given PO or IV
Andere namen:
Given IV
Andere namen:
Given PO
Andere namen:
Given PO
Andere namen:
|
|
Experimenteel: Arm C (imatinib mesylate, EsPhALL chemotherapy, HSCT)
See Detailed Description |
Correlative studies Given IV
Andere namen:
Given IV
Andere namen:
Given IV
Andere namen:
Ancillary studies Given IV
Andere namen:
Given IV
Andere namen:
Given PO
Andere namen:
Given IV
Andere namen:
Given IV
Andere namen:
Given IV
Andere namen:
Given PO or IV
Andere namen:
Given IT
Andere namen:
Given IV, SC, or IT
Andere namen:
Given PO or IV
Andere namen:
Given IV
Andere namen:
Given SC or IV
Andere namen:
Given PO
Andere namen:
Given PO or IV
Andere namen:
Given IV
Andere namen:
Given PO
Andere namen:
Given IT
Andere namen:
Given PO
Andere namen:
Undergo HSCT
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Disease free survival (DFS) of Randomized Arms (standard risk [SR] Philadelphia chromosome [Ph+] acute lymphoblastic leukemia [ALL] patients)
Tijdsspanne: Up to 3 years
|
Three-year DFS and 95% confidence intervals (CI) of SR Ph+ ALL patients treated continuous imatinib mesylate with high risk Children's Oncology Group (COG)-ALL chemotherapy backbone or more intensive European (Es)PhALL chemotherapy backbone. |
Up to 3 years
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
DFS on Randomized Arms (SR Ph+ ALL and ABL-class fusion positive patients)
Tijdsspanne: Up to 3 years
|
Three-year DFS (time from randomization to relapse, second malignancy, or death in complete remission) and 95% CI of SR pediatric Ph+ and ABL-class fusion positive patients treated with continuous imatinib combined with either a high-risk COG-ALL chemotherapy backbone or the more intensive EsPhALL chemotherapy backbone. |
Up to 3 years
|
|
Feasibility of post hematopoietic stem cell transplantation (HSCT) imatinib mesylate administration after allogenic HSCT in high risk Ph+ ALL patients
Tijdsspanne: Up to 2 years
|
The proportion of patients who receive at least 75% of intended doses. |
Up to 2 years
|
|
Event free survival (EFS) of high risk pediatric Ph+ ALL patients treated with EsPhALL chemotherapy, HSCT in first complete remission, and post-HSCT imatinib mesylate
Tijdsspanne: Up to 3 years
|
Three-year EFS and 95% CI for high risk pediatric Ph+ ALL patients treated with EsPhALL chemotherapy, HSCT in first complete remission, and post-HSCT imatinib mesylate. EFS is defined as the time from the date of bone marrow for minimal residual disease (MRD) assessment at end-IB to first event (resistant disease [MRD >= 10-2 or morphologic residual disease at end of consolidation block 3], relapse, progressive disease [i.e., MRD >= 10-2 at two post-HSCT time points separated by at least 2 weeks], second malignancy, or death in complete remission), or time to last follow-up for patients without events. |
Up to 3 years
|
|
Incidence of grade 3 or higher infections in standard risk Ph+ ALL patients in the two randomized arms
Tijdsspanne: Up to 3 years
|
Evaluated according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. The rate of infections during the post IB/pre-maintenance phases of treatment will be described for each randomization group. |
Up to 3 years
|
|
EFS of all Ph+ patients
Tijdsspanne: Up to 3 years
|
Three-year EFS and 95% CI for Ph+ ALL patients. EFS here is defined as the time from enrollment until resistant disease, relapse, progressive disease post-HSCT, second malignant, or death, whichever occurs first. |
Up to 3 years
|
|
Overall survival (OS) of all Ph+ patients
Tijdsspanne: Up to 3 years
|
Three-year OS and 95% CI for Ph+ ALL patients. OS is defined as the time from study enrollment to death from any cause. |
Up to 3 years
|
|
OS of SR Ph+ patients
Tijdsspanne: Up to 3 years
|
Three-year OS (time from randomization to death from any cause) and 95% CI of SR pediatric Ph+ patients |
Up to 3 years
|
|
OS of SR Ph+ patients by randomization group
Tijdsspanne: Up to 3 years
|
Three-year OS (time from randomization to death from any cause) and 95% CI of SR pediatric Ph+ patients by randomization group: treated with continuous imatinib combined with either a high-risk COG-ALL chemotherapy backbone or the more intensive EsPhALL chemotherapy backbone. |
Up to 3 years
|
|
OS of high risk Ph+ patients
Tijdsspanne: Up to 3 years
|
Three-year OS (time from the date of MRD assessment at end-IB to death from any cause) and 95% CI of HR pediatric Ph+ patients. |
Up to 3 years
|
|
EFS of all eligibility ABL-class fusion positive ALL patients
Tijdsspanne: Up to 3 years
|
Three-year EFS (time from enrollment until resistant disease, relapse, progressive disease post-HSCT, second malignancy, or death, whichever occurs first) and 95% CI of ABL-class fusion positive patients. |
Up to 3 years
|
|
OS of all eligibility ABL-class fusion positive ALL patients
Tijdsspanne: Up to 3 years
|
Three-year OS (the time from study enrollment to death from any cause) and 95% CI of ABL-class fusion positive patients. |
Up to 3 years
|
Andere uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Incidence of toxicities associated with post-HSCT administration of imatinib mesylate
Tijdsspanne: Up to 2 years
|
Evaluated according to NCI CTCAE version 5.0. Frequencies of target toxicities in high risk patients after the initiation of post-HSCT imatinib mesylate will be described. For the high risk patients, the specific targeted toxicities will include grade 4 neutropenia, grade 4 thrombocytopenia, grade 3 or higher bilirubin, grade 4 or higher transaminitis, and grade 3 or higher infection. |
Up to 2 years
|
|
Incidence of long-term toxicities in patients treated with chemotherapy plus imatinib mesylate (no transplant) in both arms
Tijdsspanne: Up to 3 years
|
Evaluated according to NCI CTCAE version 5.0. Frequencies of long-term toxicities will be described and differences between randomized arms will be explored. Specific long-term toxicities to be explored include cardiac (echocardiographic abnormalities, including decreased left ventricular (LV) function and decreased LV wall thickness), growth (linear height, bone age), and second malignant neoplasm. |
Up to 3 years
|
|
MRD measured by IGH-T cell receptor (TCR) polymerase chain reaction (PCR) and next generation sequencing (NGS) assay
Tijdsspanne: Up to 6 months
|
For all patients, frequencies and prognostic significance (DFS, EFS, OS) will be explored for MRD levels (i.e., MRD negative, detectable at < 5 x 10^-4, and dectectable at >= 5 x 10^-4) at end of Induction IB. |
Up to 6 months
|
|
MRD in high risk Ph+ patients measured by IGH-TCR PCR and NGS assay
Tijdsspanne: Up to 3 years
|
The outcome of high risk Ph+ patients will be described, including proportion of patients who achieve MRD-negativity just prior to HSCT, and at regular intervals post-HSCT. Associations between these findings and long-term outcomes (e.g., OS, DFS) will be explored. |
Up to 3 years
|
|
MRD assessments made by IGH-TCR PCR assay and NGS assay
Tijdsspanne: Up to 3 years
|
Concordance of MRD assessments made by IGH-TCR PCR assay and NGS assay will be described and evaluated. Scatter plots and diagrams will be used to examine agreements and patterns of agreement or any differences found. Concordance will be explored both for the overall cohort, as well as by risk group. The increased sensitivity of the NGS will be closely examined to find cases where the MRD levels are detectable by NGS but undetectable by PCR, as well as cases in which one test yields results and the other does not (test failure). Prognostic relationships on outcomes for these subjects will be inspected. |
Up to 3 years
|
|
IKZF1 deletions alone
Tijdsspanne: Up to 3 years
|
Will determine and validate if IKZF1 deletions alone predict poor outcomes in Ph+/ABL-class Ph-like ALL in patients treated on AALL1631. |
Up to 3 years
|
|
IKZF1 deletions with other transcription factor deletions
Tijdsspanne: Up to 3 years
|
Will determine and validate if IKZF1 deletions with other transcription factor deletions predict poor outcomes in Ph+/ABL-class Ph-like ALL in patients treated on AALL1631. |
Up to 3 years
|
|
Other identified genetic lesions
Tijdsspanne: Up to 3 years
|
Will determine and validate if other identified genetic lesions predict poor outcomes in Ph+/ABL-class Ph-like ALL in patients treated on AALL1631. |
Up to 3 years
|
|
Frequency of p190 and p210 BCR::ABL1 fusion variants
Tijdsspanne: Up to 3 years
|
For both standard risk and high risk groups, frequencies and prognostic significance (OS, DFS) will be explored for p190 and p210 BCR::ABL1 fusion variants in pediatric Ph+ ALL/ABL-class Ph-like ALL. |
Up to 3 years
|
|
Adherence to oral chemotherapeutic agents in standard risk Ph+ ALL patients
Tijdsspanne: Up to 2 years
|
Adherence to imatinib mesylate, 6-mercaptopurine, and methotrexate will be evaluated in COG-enrolled participants using an electronic monitoring device. Adherence rate will be computed for each month of adherence monitoring. Longitudinal binomial regression will be conducted using generalized estimating equation methods by modeling monthly adherence rate as an unstructured mean model using five indicator variables of time for the study months. Time in months will also be treated as a continuous variable to explore temporal trends in adherence rate. Compound symmetry will be assumed as the working correlation matrix over time. Covariates that will be considered for adjustment include those hypothesized to be predictors of adherence, annual household income, parental education, time since start of maintenance, risk classification for ALL, and imatinib, 6-mercaptopurine (6MP), and methotrexate dose-intensity. |
Up to 2 years
|
|
Adherence to imatinib mesylate after allogeneic HSCT in high risk Ph+ ALL patients
Tijdsspanne: Up to 2 years
|
Longitudinal binomial regression will be conducted using generalized estimating equation methods by modeling monthly adherence rate as an unstructured mean model using five indicator variables of time for the study months. Time in months will also be treated as a continuous variable to explore temporal trends in adherence rate. Compound symmetry will be assumed as the working correlation matrix over time. Covariates that will be considered for adjustment include those hypothesized to be predictors of adherence, annual household income, parental education, time since start of maintenance, risk classification for ALL, and imatinib, 6MP, and methotrexate dose-intensity. |
Up to 2 years
|
|
DFS of SR ABL-class fusion positive patients
Tijdsspanne: Up to 3 years
|
Three-year DFS (time from randomization to relapse, second malignancy, or death in complete remission) and 95% CI of SR pediatric ABL-class fusion positive patients treated with continuous imatinib combined with either a high-risk COG-ALL chemotherapy backbone or the more intensive EsPhALL chemotherapy backbone. |
Up to 3 years
|
|
Secondary and exploratory aims applied to ABL-class fusion positive patients
Tijdsspanne: Up to 3 years
|
Secondary and exploratory aims described above for Ph+ ALL patients (either SR or HR), if applicable, will be evaluated in ABL-class fusion positive ALL patients. |
Up to 3 years
|
|
Therapeutic impact of major secondary events
Tijdsspanne: Up to 3 years
|
Will determine the potential therapeutic impact of major secondary events via pharmacologic inhibitor screens in existing/engineered cell models of Ph+ and ABL-class Ph-like ALL harboring secondary events. |
Up to 3 years
|
|
Secondary and exploratory aims applied to super-set of Ph+ and ABL-class fusion positive patients
Tijdsspanne: Up to 3 years
|
Secondary and exploratory aims described above for Ph+ ALL patients (either SR or HR), if applicable, will be evaluated in the superset of Ph+ and ABL-class fusion positive ALL patients. |
Up to 3 years
|
|
In vivo activity
Tijdsspanne: Up to 3 years
|
Will test the in vivo activity of the most compelling candidate compounds from pilot studies using patient-derived xenograft models established from Ph+ and ABL-class Ph-like ALL samples collected from patients treated on AALL1631. |
Up to 3 years
|
|
Molecular heterogeneity
Tijdsspanne: Up to 3 years
|
Will decipher the molecular heterogeneity of chronic myelogenous leukemia (CML)-like versus typical Ph+ ALL via single-cell genomics and functional assays. |
Up to 3 years
|
|
Cellular heterogeneity
Tijdsspanne: Up to 3 years
|
Will decipher the cellular heterogeneity of CML-like versus typical Ph+ ALL via single-cell genomics and functional assays. |
Up to 3 years
|
|
CML-like phenotypes
Tijdsspanne: Up to 3 years
|
Will investigate CML-like phenotypes via single-cell ribonucleic acid and deoxyribonucleic acid sequencing to identify distinct transcriptomic and mutational profiles that will provide novel opportunities for diagnostic and therapeutic interventions. |
Up to 3 years
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: Lewis B Silverman, Children's Oncology Group
- Hoofdonderzoeker: Andrea Biondi, EsPhALL Network/ BFM Study Group
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Geschat)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Neoplasmata
- Ziekten van het immuunsysteem
- Infecties
- Virusziekten
- Neoplasmata per histologisch type
- Hematologische ziekten
- DNA-virusinfecties
- Lymfatische ziekten
- Lymfoproliferatieve aandoeningen
- Immunoproliferatieve aandoeningen
- Lymfoom, non-Hodgkin
- Lymfoom, B-cel
- Lymfoom
- Leukemie, Lymfoïde
- Leukemie
- Epstein-Barr-virusinfecties
- Herpesviridae-infecties
- Tumorvirusinfecties
- Hemische en lymfatische ziekten
- Voorlopercel lymfoblastische leukemie-lymfoom
- Burkitt lymfoom
- Precursor T-cel lymfoblastische leukemie-lymfoom
- Leukemie, bifenotypisch, acuut
- Hormonen
- Hormonen, hormoonvervangers en hormoonantagonisten
- Peptiden
- Aminozuren, peptiden en eiwitten
- Eiwitten
- Zwavelverbindingen
- Organische chemicaliën
- Heterocyclische verbindingen, 1-ring
- Heterocyclische verbindingen
- Heterocyclische verbindingen, 2-ring
- Heterocyclische verbindingen, gefuseerd ring
- Therapeutica
- Chirurgische procedures, operatief
- Nucleïnezuren, nucleotiden en nucleosiden
- Koolwaterstoffen
- Koolwaterstoffen, cyclisch
- Biologische factoren
- Koolhydraten
- Carbonzuren
- Alkaloïden
- Podophyllotoxine
- Tetrahydronaftalenes
- Naftalenen
- Polycyclische aromatische koolwaterstoffen
- Koolwaterstoffen, aromatisch
- Polycyclische verbindingen
- Glucosiden
- Glycosiden
- Transplantatie
- Amides
- Hydrolasen
- Enzymen
- Enzymen en co -enzymen
- Indolen
- Purines
- Cytidine
- Pyrimidine -nucleosiden
- Pyrimidines
- Zwangerschap
- Zwangere
- Steroïden
- Verbindingen met gefuseerde ring
- Steroïden, gefluoreerd
- Benzeenderivaten
- Sulfonzuren
- Zwavelzuren
- Fosforamide mosterd
- Stikstofmosterdverbindingen
- Mosterdverbindingen
- Koolwaterstoffen, gehalogeneerd
- Fosforamides
- Organofosforverbindingen
- Nucleosiden
- Formyltetrahydrofolates
- Tetrahydrofolaten
- Foliumzuur
- Pterins
- Pteridines
- Intercellulaire signaalpeptiden en eiwitten
- Zwangerschap
- Amidohydrolasen
- Vinca -alkaloïden
- Secologanin tryptamine alkaloïden
- Indol alkaloïden
- Indolizidines
- Indolizines
- Arabinonucleosides
- Aminopterine
- Antracyclines
- Naftacenes
- Aminoglycosides
- Co -enzymen
- Glycoproteïnen
- Glycoconjugaten
- Zwangeringen
- Zwangeres
- Celtransplantatie
- Op cellen en weefsel gebaseerde therapie
- Biologische therapie
- 11-hydroxycorticosteroïden
- Hydroxycorticosteroïden
- Bijnierschorshormonen
- 17-hydroxycorticosteroïden
- Oxazines
- Zuren, carbocyclisch
- Benzenesulfonaten
- Arylsulfonaten
- Arylsulfonzuren
- Benzoaten
- Kolonie-stimulerende factoren
- Hematopoietische celgroeifactoren
- Cytokines
- Benzamides
- Piperazines
- Sulfhydrylverbindingen
- Dispipiperazines
- Imatinib-mesylaat
- Dexamethason
- Methotrexaat
- Prednisolon
- Cyclofosfamide
- Cytarabine
- Etoposide
- Leucovorin
- Levoleucovorine
- Doxorubicine
- Vincristine
- Methylprednisolon
- Daunorubicine
- Hydrocortison
- Asparaginase
- Mercaptopurine
- Dexrazoxaan
- Razoxaan
- Thioguanine
- Ifosfamide
- Calciumdobesilaat
- Stamceltransplantatie
- Dexamethason 21-fosfaat
- Granulocyt kolonie-stimulerende factor
- Filgrastim
- calaspargase pegol
- azathiopurine
- Merphos
- pegaspargase
- auricularum
- Dexamethason acetaat
- exifone
- Medrol veriderm
Andere studie-ID-nummers
- AALL1631
- U10CA180886 (Subsidie/contract van de Amerikaanse NIH)
- 2017 (Subsidie/contract van de Amerikaanse NIH)
- AALL1631 (Andere identificatie: CTEP)
- NCI-2016-01588 (Register-ID: CTRP (Clinical Trial Reporting Program))
- 2017-000705-20
- 2024-515499-12-00
- AALL1631 (Andere identificatie: Children's Oncology Group)
- 2017-000705-20 (EudraCT-nummer)
- 2024-515499-12-00 (Ctis)
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .